UNSPSC 51361808: Clidafidine

This classification denotes a sedative and hypnotic with the molecular formula C9H8Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6M04D93C96, chemically known as 2-((2,6-dichlorophenyl)-imino)oxazolidine. but generally known as clidafidine, which bears US NIH Compound Identifier 193994. European Medicines Agency schedules Clidafidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06658MIG.

UNSPSC 51361808 Clidafidine, a Commodity code, shows little relevant recent activity under its nominal scope. The three most recent state and local opportunities posted under this code—a Seminole County naloxone and drug deactivation systems procurement, a Texas HHS direct-to-manufacturer prescription RFI, and a Minnesota cooperative purchasing alliance RFP for generic pharmaceuticals and OTC products—involve pharmaceutical distribution, supply chain aggregation, and wellness product procurement but do not center on clidafidine or the specific pharmaceutical class the code nominally describes. The solicitations reflect state and local agencies' actual buying patterns: county health departments sourcing opioid-reversal and harm-reduction products for community health initiatives; state health and human services commissions exploring pharmacy benefit management models; and multistate cooperative purchasing alliances establishing master contracts for generic and OTC pharmaceuticals distributed through authorized wholesale channels. Issuing bodies include county health departments, state pharmacy and health agencies, and state-led cooperative purchasing organizations serving multiple jurisdictions.

Recent geographic activity appears concentrated in the Southeast and Southwest, with Seminole County, Florida posting an IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; Texas HHS posting an RFI on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs; and the Minnesota Department of Administration (on behalf of MMCAP, the Minnesota Multistate Cooperative Purchasing Alliance) issuing an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, and contract effectiveness of July 1, 2026. The mismatch between the code's nominal pharmaceutical class and the actual scope of posted opportunities suggests the code may not reflect current state and local procurement patterns for this product category.